National Foundation for Cancer Research (NFCR) posted on LinkedIn:
“Breakthrough Alert: A leukemia drug may help kids with brain cancer.
New research from NFCR-supported scientist Dr. Rakesh K. Jain at Massachusetts General Hospital Cancer Center suggests that dasatinib (Sprycel), already FDA-approved for leukemia, could be repurposed to treat pediatric ependymoma, a rare and treatment-resistant brain tumor.
By blocking tumor-supporting pathways and reactivating the immune system, dasatinib shows promise in slowing tumor growth and enhancing immune response. This discovery could pave the way for clinical trials and much-needed treatment options for children battling ependymoma.
Read more about this exciting research.”
